Pelareorep - Oncolytics Biotech

Next Previous
Drug Profile

Pelareorep - Oncolytics Biotech

Alternative Names: PO-BB0209; REOLYSIN; Reosyn; Reovirus; Reovirus - Oncolytics Biotech; Reovirus anticancer; Reovirus antitumour; Reovirus Serotype 3 - Dearing Strain; Respiratory Enteric Orphan virus

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncolytics Biotech
  • Developer Mayo Clinic; National Cancer Institute (Canada); National Cancer Institute (USA); Oncolytics Biotech; University of Leeds; University of Southern California
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fallopian tube cancer; Glioma; Peritoneal cancer; Ovarian cancer; Gastric cancer; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Head and neck cancer
  • Phase II Brain cancer; Breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma
  • Phase I/II Glioma
  • Phase I Multiple myeloma
  • Preclinical Hepatocellular carcinoma; Viral hepatitis
  • No development reported Solid tumours

Most Recent Events

  • 18 Apr 2018 Pharmacodynamics data from a preclinical study in Colorectal cancer released by Oncolytics Biotech
  • 17 Apr 2018 Oncolytics Biotech applies for a Special Protocol Assessment with the US FDA to conduct a pivotal phase III trial for Breast cancer (Metastatic disease)
  • 10 Apr 2018 Pharmacodynamics data from a preclinical trial in Prostate cancer released by Oncolytics Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top